A Risk-Benefit Assessment of Buspirone in the Treatment of Anxiety Disorders
- 1 February 1997
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 16 (2) , 118-132
- https://doi.org/10.2165/00002018-199716020-00004
Abstract
Anxiety disorders include generalised anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD) and social phobia. Consideration of the chronicity of these disorders reveals that anxiety...Keywords
This publication has 98 references indexed in Scilit:
- Pharmacotherapy of Social PhobiaThe British Journal of Psychiatry, 1992
- Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitorEuropean Neuropsychopharmacology, 1992
- Drug Treatment of Panic Disorder: Comparative Efficacy of Alprazolam, Imipramine, and PlaceboThe British Journal of Psychiatry, 1992
- Treatment of Comorbid Deneralized Anxiety in a Recently Detoxified Alcoholic Population with a Selective Serotonergie Drug (Buspirone)Current Opinion in Cardiology, 1992
- A Double-Blind Study of Adjuvant Buspirone Hydrochloride in Clomipramine-Treated Patients with Obsessive-Compulsive DisorderCurrent Opinion in Cardiology, 1992
- Problems with the differentiation of anxiety and depressionJournal of Psychiatric Research, 1989
- Suicidal Ideation and Suicide Attempts in Panic Disorder and AttacksNew England Journal of Medicine, 1989
- Use of Psychoactive Medication and the Quality of Care in Rest HomesNew England Journal of Medicine, 1989
- Psychotropic Drug Use and the Risk of Hip FractureNew England Journal of Medicine, 1987
- Combined pharmacological and behavioral treatment for agoraphobiaBehaviour Research and Therapy, 1985